Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Analysts
by Mitch Edgeman · The Markets DailyShares of Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) have been given an average recommendation of “Hold” by the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $21.6667.
Several equities research analysts recently commented on PRTA shares. Royal Bank Of Canada increased their price objective on Prothena from $11.00 to $12.00 and gave the company a “sector perform” rating in a research report on Friday, February 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prothena in a research note on Monday, December 29th. Citigroup reissued a “market outperform” rating on shares of Prothena in a report on Friday, March 13th. Finally, Stifel Nicolaus set a $19.00 price objective on Prothena in a research report on Friday, March 13th.
Read Our Latest Report on Prothena
Prothena Stock Performance
NASDAQ:PRTA opened at $9.86 on Friday. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $11.84. The firm has a market cap of $530.76 million, a PE ratio of -2.17, a price-to-earnings-growth ratio of 0.67 and a beta of -0.33. The business has a 50 day moving average price of $9.17 and a 200-day moving average price of $9.61.
Prothena (NASDAQ:PRTA – Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.67 million. Prothena had a negative return on equity of 65.89% and a negative net margin of 2,520.57%. Research analysts predict that Prothena will post -4.04 EPS for the current year.
Institutional Trading of Prothena
Several hedge funds have recently modified their holdings of the company. Intech Investment Management LLC grew its position in Prothena by 5.5% in the third quarter. Intech Investment Management LLC now owns 19,388 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 1,014 shares in the last quarter. Brooklyn Investment Group raised its position in Prothena by 13.1% during the third quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,456 shares during the period. Deutsche Bank AG lifted its stake in shares of Prothena by 5.1% in the 4th quarter. Deutsche Bank AG now owns 35,482 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 1,709 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Prothena by 3.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 81,515 shares of the biotechnology company’s stock valued at $779,000 after purchasing an additional 2,968 shares during the last quarter. Finally, Virtus Investment Advisers LLC boosted its holdings in shares of Prothena by 14.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 25,679 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 3,236 shares during the period. 97.08% of the stock is owned by hedge funds and other institutional investors.
Prothena Company Profile
Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.
The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.